跳至主要内容
临床试验/CTRI/2020/05/025147
CTRI/2020/05/025147招募中2 期

Comprehensive Genomic Profiling by Next Generation Sequencing (Foundation Medicine) Of Advanced Biliary Tract Cancers (Gallbladder, Cholangiocarcinoma) And Guided Treatment: A Phase 2, Prospective, Multicenter Study.

Armed Forces Medical Research Committee0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histologically proven cases of adenocarcinoma of gallbladder and Cholangiocarcinoma.
  • Locally advanced, unresectable or metastatic disease
  • ECOG Performance status <2
  • Adequate bone marrow function reflected
  • Hemoglobin > 8 gm/dl, TLC > 4,000/cumm
  • (ANC >1,500/cumm), and Platelets >1,00,000/cumm)
  • Serum creatinine <1.8 mg%
  • Serum bilirubin < 3 mg%
  • Liver enzymes (SGOT and SGPT) within 3 times the
  • upper normal limit
  • No prior exposure to gemcitabine, Oxaliplatin, cisplatin, capecitabine or radiation therapy

排除标准

  • Women of reproductive age group not practicing
  • contraception.
  • Lactating and pregnant women.
  • History of previous carcinoma in last 5 yrs.
  • Active hepatitis B, C or HIV infection.

研究者

发起方
Armed Forces Medical Research Committee

相似试验